2019
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortexRandomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance
Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. Substance Use & Addiction Journal 2019, 40: 132-135. PMID: 30714880, PMCID: PMC6874094, DOI: 10.1080/08897077.2019.1569192.Peer-Reviewed Original ResearchConceptsOffice-based buprenorphineOpioid use disorderBuprenorphine treatmentWeb-based interventionBuprenorphine maintenancePilot trialUse disordersBehavioral careCurrent opioid use disorderOffice-based buprenorphine treatmentUrine toxicology screenSpecific patient populationsDays of treatmentDSM-5 criteriaCognitive behavioral therapyInitial pilot testingToxicology screenPatient populationTwelve-weekEffective treatmentBuprenorphineDrug useSmall sample sizeTrialsPromising findings
2018
Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersAn investigation of an open‐access model for scaling up methadone maintenance treatment
Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction 2018, 113: 1450-1458. PMID: 29453891, DOI: 10.1111/add.14198.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderMethadone maintenance treatmentOpioid useMaintenance treatmentTreatment accessUse disordersTreatment modelMethadone maintenance treatment centersMaintenance treatment centersDeleterious effectsMethadone treatmentPatient mortalityTreatment optionsTreatment outcomesTreatment centersProspective patientsRate of retentionPatient censusRapid enrollmentAddiction treatmentApparent deleterious effectsTreatmentMortalityProgrammatic outcomes
2017
Effect of doxazosin on stress reactivity and the ability to resist smoking
Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. PMID: 28440105, PMCID: PMC5823502, DOI: 10.1177/0269881117699603.Peer-Reviewed Original ResearchConceptsTobacco cravingCortisol levelsSubsequent ad libitum smokingEffects of doxazosinAd libitum smokingNumber of cigarettesNicotine-motivated behaviorsSmoking lapse behaviorΑ1-adrenergic antagonistNicotine-deprived smokersTitration periodPreclinical findingsSmoking cessationNoradrenergic systemTreatment strategiesDoxazosinSmoking behaviorSmokingHuman laboratoryPhysiologic reactivityPilot studyStress reactivityEffects of stressCigarettesStress imagery
2016
Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol Self-AdministrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomes
2014
Ethyl Glucuronide and Ethyl Sulfate Assays in Clinical Trials, Interpretation, and Limitations: Results of a Dose Ranging Alcohol Challenge Study and 2 Clinical Trials
Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, Nogueira C, Shi J, Dziura JD, Petrakis IL, O'Malley SS. Ethyl Glucuronide and Ethyl Sulfate Assays in Clinical Trials, Interpretation, and Limitations: Results of a Dose Ranging Alcohol Challenge Study and 2 Clinical Trials. Alcohol Clinical And Experimental Research 2014, 38: 2056-2065. PMID: 24773137, PMCID: PMC4107122, DOI: 10.1111/acer.12407.Peer-Reviewed Original ResearchConceptsEtG/EtSClinical trialsEthyl glucuronideRecent alcohol consumptionEvaluation of outcomesAlcohol challenge studyBlood concentrationsAlcohol dosesLow doseLight drinkingAlcohol consumptionChallenge studiesCutoff concentrationDrinking historyTimed intervalsAbstinenceTrialsHeavy consumptionDrinkingDoseGlucuronideObjective measuresHoursCutoffEtG
2013
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration
Udo T, Harrison EL, Shi J, Tetrault J, McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration. American Journal On Addictions 2013, 22: 590-597. PMID: 24131167, PMCID: PMC3934424, DOI: 10.1111/j.1521-0391.2013.12014.x.Peer-Reviewed Original ResearchConceptsSelf-administration periodNicotine nasal sprayHeavy drinking smokersNasal sprayNicotine patchAlcohol responsesPriming drinkSerum nicotine levelsPlacebo-controlled studyNicotine replacement therapySubjective alcohol responsesPositive subjective responsesNumber of drinksPlacebo administrationReplacement therapyPriming doseSmoking relapseAlcohol consumptionPlacebo conditionPatch applicationNicotine levelsClinical settingPilot studySmokersSubjective responses
2012
Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational work
2007
Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration
McKee SA, O’Malley S, Shi J, Mase T, Krishnan-Sarin S. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology 2007, 196: 189-200. PMID: 17912500, PMCID: PMC2862181, DOI: 10.1007/s00213-007-0952-3.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdultAlcohol DrinkingBlood PressureChromatography, High Pressure LiquidDose-Response Relationship, DrugDouble-Blind MethodDrinking BehaviorFemaleHeart RateHumansMaleMiddle AgedMonitoring, PhysiologicNicotineOscillometrySelf AdministrationSelf-AssessmentSkin TemperatureSmoking PreventionSpectrophotometry, UltravioletSurveys and QuestionnairesTime FactorsConceptsTransdermal nicotine replacementNicotine replacementSelf-administration periodPriming drinkHeavy drinkersPatch applicationNicotine deprivationAlcohol responsesNicotine patch conditionPlacebo patch conditionDouble-blind studySystolic blood pressureHeavy drinking smokersPatch conditionsAlcohol drinking behaviorTransdermal patch applicationDrinking behaviorInitiation of drinkingBlood pressurePlacebo patchAdditional drinkDaily smokersTobacco cravingTobacco useHeart rate
2006
Modeling the effect of alcohol on smoking lapse behavior
McKee SA, Krishnan-Sarin S, Shi J, Mase T, O’Malley S. Modeling the effect of alcohol on smoking lapse behavior. Psychopharmacology 2006, 189: 201-210. PMID: 17013640, PMCID: PMC2862311, DOI: 10.1007/s00213-006-0551-8.Peer-Reviewed Original ResearchConceptsFirst cigaretteSelf-administration sessionsNovel human laboratory modelPoor smoking cessation outcomesSmoking cessation outcomesSmoking lapse behaviorHuman laboratory modelEffects of alcoholSecondary outcomesAlcohol drinkersLapse behaviorMore cigarettesNicotine withdrawalCessation outcomesRisk factorsDaily smokersSubsequent smokingTobacco cravingPlacebo beverageTobacco relapseSmoking sessionHeavy social drinkersPriming drinkAlcohol consumptionAlcohol useHigh Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results
Friedman LN, Nash ER, Bryant J, Henry S, Shi J, D'Amato J, Khaled GH, Russi MB, O'Connor PG, Edberg SC, Pisani MA, Cain HC, Tanoue L, Weissman DN. High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results. Infection Control And Hospital Epidemiology 2006, 27: 436-441. PMID: 16671022, DOI: 10.1086/503690.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB testTuberculin skin testPrevious tuberculin skin testTST statusInitial tuberculin skin testPositive tuberculin skin testSecond tuberculin skin testPositive skin test resultsExperienced healthcare workersNegative TST resultsTST-negative groupSkin test resultsTST protocolWhole blood assaysNegative resultsPositive resultsTuberculosis exposureImmunocompetent subjectsQuantiFERON testSkin testTST resultsMedical recordsInduration diameterHealthcare workersHigh risk
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
1997
Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals Of Internal Medicine 1997, 127: 526-30. PMID: 9313020, DOI: 10.7326/0003-4819-127-7-199710010-00004.Peer-Reviewed Original ResearchConceptsPrimary care settingOpioid detoxificationCare settingsBuprenorphine groupWithdrawal symptomsDouble-blind clinical trialOpioid-dependent patientsHeroin-dependent patientsPrimary care clinicsWithdrawal symptom scoresSevere withdrawal symptomsDrug treatment programsSubstance abuse treatmentNaltrexone groupCare clinicsSymptom scoresPharmacologic protocolClinical trialsTreatment protocolClonidineTreatment retentionBuprenorphineNaltrexoneTreatment programAbuse treatment